A detailed history of Dimensional Fund Advisors LP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 836,195 shares of DAWN stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
836,195
Previous 888,117 5.85%
Holding current value
$10.6 Million
Previous $12.2 Million 4.82%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$12.72 - $16.03 $660,447 - $832,309
-51,922 Reduced 5.85%
836,195 $11.6 Million
Q2 2024

Aug 09, 2024

SELL
$12.03 - $17.69 $1.12 Million - $1.65 Million
-93,455 Reduced 9.52%
888,117 $12.2 Million
Q1 2024

May 10, 2024

BUY
$13.56 - $17.46 $2.76 Million - $3.56 Million
203,655 Added 26.18%
981,572 $16.2 Million
Q4 2023

Feb 07, 2024

BUY
$9.68 - $15.37 $4.57 Million - $7.25 Million
471,732 Added 154.07%
777,917 $11.4 Million
Q3 2023

Nov 09, 2023

BUY
$11.22 - $14.86 $1.38 Million - $1.83 Million
123,007 Added 67.15%
306,185 $3.76 Million
Q2 2023

Aug 09, 2023

SELL
$11.74 - $14.47 $2.12 Million - $2.62 Million
-180,881 Reduced 49.68%
183,178 $2.19 Million
Q1 2023

May 12, 2023

BUY
$12.75 - $23.41 $2.87 Million - $5.28 Million
225,451 Added 162.65%
364,059 $4.87 Million
Q4 2022

Feb 09, 2023

BUY
$18.77 - $22.0 $1.64 Million - $1.92 Million
87,200 Added 169.62%
138,608 $2.98 Million
Q3 2022

Nov 10, 2022

BUY
$16.44 - $26.57 $845,147 - $1.37 Million
51,408 New
51,408 $1.03 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $927M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.